Aeras, Rockville, MD 20850, USA.
Vaccine. 2012 Apr 16;30(18):2811-23. doi: 10.1016/j.vaccine.2012.02.036. Epub 2012 Mar 3.
In this review, published peer-reviewed preclinical studies using prime-boost tuberculosis (TB) vaccine regimens in animal challenge models for tuberculosis have been evaluated. These studies have been divided into groups that describe prime-boost vaccine combinations that performed better than, equivalent to, or worse than the currently used BCG vaccine. Review of the data has revealed interesting findings, including that more than half of the published studies using BCG as a prime combined with a novel boost vaccine give better efficacy than BCG alone and that the greatest reduction in Mycobacterium tuberculosis (M.tb.) colonization of animal tissues is provided by viral vectored vaccines delivered intranasally. Careful evaluation of these data should assist in defining the value of prime-boost regimens for advancement into human TB vaccine trials and stimulate the development of criteria for choosing which vaccine candidates should be studied further.
在这篇综述中，评估了已发表的使用在动物挑战模型中针对结核病的加强型结核（TB）疫苗方案的同行评审临床前研究。这些研究分为描述加强型疫苗组合的组，这些疫苗组合在效果上优于、等同于或劣于目前使用的卡介苗（BCG）疫苗。对数据的审查揭示了有趣的发现，包括超过一半的使用卡介苗作为初始疫苗并结合新型加强疫苗的已发表研究比单独使用卡介苗的效果更好，并且通过鼻腔内给予病毒载体疫苗可以最大程度地减少动物组织中结核分枝杆菌（M.tb.）的定植。对这些数据的仔细评估应该有助于确定加强型疫苗方案在推进人类结核病疫苗试验中的价值，并激发制定选择应进一步研究哪些疫苗候选物的标准。
